Why uniQure shares are sinking after AMT-130 update

uniQure shares plunged after four-year data for Huntington’s gene therapy AMT-130 showed weaker disease-progression slowing than earlier results. While 48-month TFC data remained e

Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to economictimes.indiatimes.com's own reporting rather than reproducing it — the excerpt above comes from economictimes.indiatimes.com's own feed.